Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients All trial patients treated with TG4050 monotherapy continue to remain in remission

Related Keywords

France , Zeiten , Mecklenburg Vorpommern , Germany , United Kingdom , Ankara , Turkey , Chicago , Illinois , United States , Joseph Jasper , Stefan Klotter , Institut Curie , Masamitsu Kitase , Transgene Euronext , Jean Pierre Delord , Sylvie Berrebi , Alexandra Martinez , Le Tourneau , Christophe Le Tourneau , Alessandro Riva , Lucie Larguier , Yujie Zhao , Christian Ottensmeier , American Society Of Clinical Oncology , Twitter , Head Of Surgical Department , Ai Drug Development Division , Corporate Communications , Nec Ai Drug Development Business , Clatterbridge Cancer Centre , Life Science Division , University Of Liverpool , Head Of The Department Drug Development , Euronext Paris , American Society , Clinical Oncology , Annual Meeting , Corporate Senior , Serious Adverse Events , Consultant Medical Oncologist , Drug Development , Consultant Medical Oncology , Consultant Immunology , Associate Professor , Mayo Clinic , Associate Head , Surgical Department , Vaccinia Ankara , Artificial Intelligence , Prediction System , Development Business , Risk Factors , Universal Registration Document , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Transgene , Present , Data , G4050 , Individualized , Dancer , Vaccine , Showing , Induces , Specific , Immune , Responses , Against , Head , Neck , Arcinoma , Disco , 023 ,